12 de diciembre de 2019
  • Miércoles, 11 de Diciembre
  • 28 de junio de 2010

    Kowa Company, Ltd. Grants Abbott Exclusive Rights to Market Pitavastatin Calcium, a Lipid-lowering Drug, in Australia an


    Country/area Current status Launched (or Distributors
    expected)
    Japan Launched September 2003 Kowa Soyaku Co., Ltd,
    Daiichi Sankyo Co., Ltd.*1
    Korea Launched July 2005 Choongwae Pharma Corporation
    Thailand Launched January 2008 BioPharma Chemical
    China Launched July 2009 *2
    USA Approved 2010 2Q *3
    EU Submitted 2010 *4
    Canada Submitted 2011 Abbott
    Taiwan Submitted 2011 Tai Tien Pharmaceuticals Co.,
    Ltd. (Tanabe Mitsubishi
    Pharma Co.)
    Middle East/ Preparing for 2011
    North Africa submission Algorithm SAL
    Latin Preparing for 2011
    America submission Eli Lilly
    Indonesia Preparing for 2012 Tanabe Indonesia
    submission (Tanabe Mitsubishi Pharma Co.)
    Australia/ Preparing for 2012
    New Zealand submission Abbott

    *1. The annual sales of Livalo tablets in Japan reached 41 billion yen in 2009.

    *2 Kowa (Shanghai) Pharma Consulting. Co., Ltd., a wholly-owned subsidiary of Kowa, is obtaining and providing information to physicians and hospitals in China to ensure proper use of pitavastatin.

    *3 Co-promotional activities in the United States will be conducted by Kowa. Pharmaceutical America, Inc. (headquarters in Alabama), a distributor owned by Kowa, and Eli Lilly.

    *4 In Europe, pitavastatin will be distributed by Kowa Pharmaceutical Europe Co., Ltd. (Headquarters in Wokingham, UK), a wholly-owned subsidiary of Kowa, and Recordati (Headquarters in Milan, Italy), a partner distributor.

    About Kowa

    Kowa Company, Ltd. (KCL) is a privately held multinational company headquartered in Nagoya, Japan. Established in 1894, KCL is actively engaged in various manufacturing and commercial activities in the fields of pharmaceutical, life science, information technology, textiles, machinery and various consumer products. KCL's pharmaceutical division was founded in 1946, and is focused on cardiovascular therapeutics, with sales of the company's flagship product, LIVALO, totaling $440 million (14% market share) in Japan during the last fiscal year and expected to exceed $600 million in the near future.

    Kowa Pharmaceuticals America, Inc. (KPA) is a specialty pharmaceutical company focused primarily in the area of cardiometabolic therapeutics. The company, started in 2001 as ProEthic Pharmaceuticals, Inc., was acquired by KCL in September of 2008. A privately held company, KPA focuses its efforts on the acquisition, development, licensing and marketing of pharmaceutical products. Its lead product, LIPOFEN(R) (fenofibrate capsules), is indicated as adjunctive therapy to diet to reduce elevated TG and to increase HDL-C in adult patients with primary hypercholesterolemia or mixed dyslipidemia.

    Kowa Research Europe, Ltd. (KRE), established in 1999 in the United Kingdom, is responsible for European clinical trials for Kowa's strategic global pharmaceutical development.

    About Abbott

    [TAB]

    Company name Abbott

    Established in 1888

    Chairman and CEO Miles D. White

    Headquarters Abbott Park, Illinois

    Employees About 83,000 worldwide

    2009 Revenue $30.8 billion USD

    Abbott products marketed More than 130

    in countries

    [FTAB]

    About Recordati

    Recordati, established in 1926, is a European pharmaceutical group, listed on the Italian Stock Exchange (Reuters RECI.MI, Bloomberg REC IM, ISIN IT 0003828271),with a total staff of over 2,950, dedicated to the research, development, manufacturing and marketing of pharmaceuticals. It has headquarters in Milan, Italy, operations in the main European countries, and a growing presence in the new markets of Central and Eastern Europe. A European field force of over 1,450 medical representatives promotes a wide range of innovative pharmaceuticals, both proprietary and under license, in a number of therapeutic areas including a specialized business dedicated to treatments for rare diseases. Recordati's current and growing coverage of the European pharmaceutical market makes it a partner of choice for new product licenses from companies which do not have European marketing organizations.

    (CONTINUA)


    Company name Abbott
    Established in 1888
    Chairman and CEO Miles D. White
    Headquarters Abbott Park, Illinois
    Employees About 83,000 worldwide
    2009 Revenue $30.8 billion USD
    Abbott products marketed More than 130
    in countries

    About Recordati

    Recordati, established in 1926, is a European pharmaceutical group, listed on the Italian Stock Exchange (Reuters RECI.MI, Bloomberg REC IM, ISIN IT 0003828271),with a total staff of over 2,950, dedicated to the research, development, manufacturing and marketing of pharmaceuticals. It has headquarters in Milan, Italy, operations in the main European countries, and a growing presence in the new markets of Central and Eastern Europe. A European field force of over 1,450 medical representatives promotes a wide range of innovative pharmaceuticals, both proprietary and under license, in a number of therapeutic areas including a specialized business dedicated to treatments for rare diseases. Recordati's current and growing coverage of the European pharmaceutical market makes it a partner of choice for new product licenses from companies which do not have European marketing organizations.

    (CONTINUA)